Viracta Therapeutics, Inc. Stock Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 2.33M | Capitalization | 28.87M |
---|---|---|---|---|---|
Net income 2024 * | -62M | Net income 2025 * | -83M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 12.4 x |
P/E ratio 2024 * |
-0.64
x | P/E ratio 2025 * |
-0.69
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.2% |
Latest transcript on Viracta Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 61 | 22-09-18 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-08-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 07-09-30 |
Thomas Darcy
BRD | Director/Board Member | 74 | 21-01-31 |
Barry Simon
BRD | Director/Board Member | 59 | 21-03-02 |
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |